Meglumine antimoniate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Systematic (IUPAC) name
Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Legal status
?
Identifiers
CAS number 133-51-7 N
ATC code P01CB01 QP51AB01
PubChem CID 64953
ChemSpider 58479 YesY
ChEMBL CHEMBL239129 YesY
NIAID ChemDB 008733
Chemical data
Formula Variable
Mol. mass Variable
 N (what is this?)  (verify)

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

See also[edit]

References[edit]

  1. ^ Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.  edit
  2. ^ Aventis press release, 15 April 2005. (German)